-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

802. Chemical Biology and Experimental Therapeutics: Poster II

Chemical Biology and Experimental Therapeutics Program: Oral and Poster Abstracts
Type: Poster
Sunday, December 6, 2015: 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Ada H.V. Repetto-Llamazares, PhD1*, Roy Hartvig Larsen, PhD2*, Landsverk Kirsti, PhD3*, Trond Stokke, PhD3*, Bergthora Eiriksdottir, PhD4*, Roman Generalov, MSc1* and Jostein Dahle, PhD1*

1Nordic Nanovector ASA, Oslo, Norway
2Sciencons, Oslo, Norway
3Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
4Articlas, Reykjavik, Iceland

Monica Galli, MD1*, Hila Magen, MD2*, Hermann Einsele3, Manik Chatterjee, MD4*, Mariella Grasso, MD5*, Giorgina Specchia6, Paola Barbieri, MD7*, David Paoletti, MS7*, Silvia Pace, MS8*, Ralph D Sanderson, PhD9*, Alessandro Rambaldi, MD10 and Arnon Nagler, MD, MSc11

1Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
2Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel
32Department of Internal Medicine. II, Wuerzburg, Germany
4Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany
5S.C Ematologia, ASO S.Croce e Carle, Cuneo, Italy
6Hematology - Dept. of Emergency and Organ Transplantation, University of Bari, Bari, Italy
7sigma-tau Research Switzerland SA, Mendrisio, Switzerland
8sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia (RM), Italy
9University of Alabama at Birmingham, Birmingham
10Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy
11Division of Hematology, Sheba Medical Center, Ramat Gan, Israel

Alyssa M. Aldridge1*, Kaitlyn M. Dykstra, PhD2*, Cheryl Allen, BS2*, Sean H. Colligan, BS3*, Eric R. Falcone, MS4*, Andrew J. Wiemer, PhD4*, Dennis L. Wright, PhD4* and Sarah A Holstein, MD, PhD2

1Brown University, Providence, RI
2Medicine, Roswell Park Cancer Institute, Buffalo, NY
3Immunology, Roswell Park Cancer Institute, Buffalo, NY
4Pharmaceutical Sciences, University of Connecticut, Storrs, CT

Michelle Degnin1*, Katherine Tarlock, MD2, Anupriya Agarwal, PhD3, Soheil Meshinchi, MD, PhD4, Cristina E. Tognon, PhD1,5* and Brian J. Druker, MD3,5

1Knight Cancer Institute, Oregon Health and Science University, Portland, OR
2Fred Hutchinson Cancer Research Center, Seattle, WA
3Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
4Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
5Howard Hughes Medical Institute, Portland, OR

Vinicius Renan Pinto Mattos, MD1*, Nelson Hamerschlak, MD, PhD1, Isabel Nagle Reis, MD1*, Dirceu Hamilton Cordeiro Campelo, MD1*, Michelle Petrolli Silveira, MD1*, Flavia Munhoz Ferreira, MD1*, Juliano Cordova Vargas, MD1*, Paulo Vidal Campregher, MD1*, Fabio P.S. Santos, MD1, Fabio R. Kerbauy, MD, PhD1*, Joao C. C. Guerra, MD, PhD1*, Claudio Galvão Castro Júnior, MD1*, Steven S. Evans, MS2* and Robert Nagourney, MD3*

1Hospital Israelita Albert Einstein, Sao Paulo, Brazil
2Rational Therapeutics, Long Beach, CA
3The Malcom Todd Cancer Institute, Long Beach, CA

Eleni-Dimitra Papanagnou1*, Tina Bagratuni2*, Efstathios Kastritis2*, Issidora Papassideri1*, Evangelos Terpos, MD2, Meletios A. Dimopoulos3 and Ioannis P. Trougakos1*

1Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Christine M Will, MS1*, Michael Scholle, MS2*, Roodolph St. Pierre, BS3*, Gary Schiltz, PhD4*, James E. Bradner, MD3, Milan Mrksich, PhD2* and Jonathan D. Licht, MD1

1Feinberg School of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL
2Department of Biomedical Engineering and Chemistry, Northwestern University, Chicago, IL
3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4Center for Molecular Innovation and Drug Discovery, Northwestern University, Chicago, IL

Mark A. Murakami, MD, MA1,2, Alexandra N. Christodoulou, M.S.1*, Amanda L Christie, B.S.1*, Tiffany DeSouza, B.S.1*, Abner Louissaint Jr., MD, PhD3, Una Vojinovic, B.S.4*, Raphael Koch, MD5*, Loretta S. Li, MD5, Scott P. Kallgren, Ph.D.2*, Prakash Rao, Ph.D.1,6*, Johannes Köster, Ph.D.1,6*, Raga Vadhi, M.S.1,6*, Eilene Duberow, B.S.1,6*, Elizabeth A. Morgan, MD7, Hongjun Wang8*, Samia S. Ahmed9*, Katharine L. Majewski9*, Marina Konopleva, MD, PhD10, Jerome Tamburini, M.D., Ph.D.11*, Alejandro Gutierrez, M.D.12, Michelle Kelliher, PhD13, Julia Etchin, PhD14*, Irmela Jeremias, MD15,16,17*, Andrew P. Weng, MD, PhD18, Andrew L Kung, MD, PhD19, Andrew A Lane, MD, PhD1, Francine Garnache-Ottou, Ph.D.20,21,22,23*, Shai Izraeli, MD, Prof24, Eric Jacobsen, MD1, Ilene Galinsky, ANP1, Richard M. Stone, MD1, Marian H. Harris, MD, PhD25*, David M. Dorfman, MD, PhD7, Jon C Aster, MD PhD26, Henry Long, Ph.D.1,6*, Lewis B. Silverman, MD27,28 and David M Weinstock, MD1

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Biomedical Informatics, Harvard Medical School, Boston, MA
3Department of Pathology, Massachusetts General Hospital, Boston, MA
4Dana Farber Cancer Institute, Boston, MA
5Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
6Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA
7Department of Pathology, Brigham and Women's Hospital, Boston, MA
8Pathology, Boston Children's Hospital, Boston, MA
9Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
10Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
11Hematology, Institut Cochin, Paris, France
12Pediatric Hematology/Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Boston, MA
13Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA
14Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston, Harvard Medical School, Boston, MA
15Research Unit Gene Vectors, Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany
16German Cancer Research Center (DKFZ), Heidelberg, Germany
17Department of Oncology, Dr. von Haunersches Kinderspital, Ludwig Maximilians University, Munich, Germany
18Terry Fox Laboratory/Dept of Pathology, BC Cancer Agency, Vancouver, BC, Canada
19Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Medical Center, New York, NY
20Université Bourgogne - Franche-Comté, Besançon, France
21INSERM, Besançon, France
22LabEX LipSTIC, Besançon, France
23EFS Bourgogne - Franche-Comté, Besançon, France
24Sheba Medical Center, Edmond and Lily Safra Children Hospital, Pediatric Hematology Oncology, Tel Hashomer, Ramat Gan and Tel Aviv University, Ramat Gan, Israel
25Department of Pathology, Boston Children's Hospital, Boston, MA
26Pathology, Brigham and Women's Hospital, Boston, MA
27Division of Pediatric Hematology, Boston Children's Hospital, Boston, MA
28Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA

Katherine K. Soh1*, Brigham L. Bahr1*, Jeremiah J. Bearss1*, Wontak Kim1*, Peter Peterson, PhD1*, Clifford J. Whatcott, PhD1*, Adam Siddiqui-Jain, PhD2*, David J. Bearss, PhD2 and Steven L. Warner, PhD2

1Discovery Biology, Tolero Pharmaceuticals, Inc., Lehi, UT
2Tolero Pharmaceuticals, Inc., Lehi, UT

Ilaria Laurenzana, PhD1*, Antonella Caivano1*, Francesco La Rocca1*, Stefania Trino, PhD1*, Luciana De Luca1*, Francesca D'Alessio2*, Cristina Tintori, PhD3*, Vittorio Simeon, PhD1*, Antonio Traficante4*, Antonella Teramo, PhD5*, Renato Zambello5*, Gianpietro Semenzato6,7*, Silvia Schenone8*, Maurizio Botta, PhD3*, Pellegrino Musto9 and Luigi Del Vecchio, MD10*

1Laboratory of pre-clinical and translational research, IRCCS Referral Cancer Center of Basilicata (CROB), Rionero in Vulture, Italy
2CEINGE-Biotecnologie Avanzate s.c.a.r.l, Federico II University, Naples, Italy
3Department of biotechnology, chemistry and pharmacy, University of Siena, Siena, Italy
4Unit of Clinical Pathology, IRCCS-Referal Cancer Center of Basilicata (CROB), Rionero in Vulture, Italy
5Department of Medicine, Hematology and Clinical Immunology Section, Padua University School of Medicine, Padua, Italy
6Department of Medicine, Hematology and Clinical Immunology, Padua School of Medicine, Padova, Italy
7Padova University School of Medicine, Padova, Italy
8Department of pharmacy, University of Genoa, Genoa, Italy
9Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy
10Flow Cytometry, DBBM, Federico II University, Naples, Italy

*signifies non-member of ASH